La lecture à portée de main
Description
Informations
Publié par | novo-nordisk |
Publié le | 02 décembre 2013 |
Nombre de lectures | 4 |
Langue | English |
Extrait
PR Newswire
COPENHAGEN, Denmark, December 2, 2013
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily[1].
To view the Multimedia News Release, please click:
http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes[2]-[4].
"Type 2 diabetes is a progressive disease and many patients who are uncontrolled with basal insulin need to add mealtime insulin to achieve or maintain their glycaemic targets over time. As Ryzodeg® is a combination of two distinct insulins, a basal insulin with a long and steady action profile and a well-established mealtime insulin, it is a simple way for patients to add mealtime control with a reduced risk of overall andnocturnal confirmed, and severe hypoglycaemia," said lead investigator Gregory Fulcher, Royal North Shore Hospital, Sydney, Australia.
The multinational BOOST™ INTENSIFY PREMIXI trial was a 26-week, randomised, controlled open-label, treat-to-target trial comparing the efficacy and safety of Ryzodeg® and biphasic insulin aspart 30, both administered twice-daily with or without oral antidiabetic drugs in adult patients with type 2 diabetes previously treated with premixed or self-mixed insulin either once- or twice-daily.
Overall study results include[1]:
About Ryzodeg®
Ryzodeg® is the global brand name forinsulin degludec/insulin aspart. It is a combination of two distinct insulin analogues, Tresiba® (insulin degludec) and NovoRapid® (insulin aspart) in the ratio of 70% and 30%. Ryzodeg® delivered twice-daily at main meals offers successful reductions in HbA1c[2] with lower rates of hypoglycaemia versus biphasic insulin aspart 30 in people with type 2 diabetes[5],[6]. Ryzodeg® has been approved in Japan, Mexico, EU, Norway, Iceland, Switzerland, El Salvador and Chile.
About the BOOST™ programme
Novo Nordisk completed the phase 3a BOOST™ programme in 2010. This programme consisted of six randomised, controlled, treat-to-target trials in more than 30 countries and comprised the majority of the data supporting the regulatory applications for Ryzodeg®. More than 2000 people were included in the development programme. The programme was designed after consultancy with regulatory agencies in Europe and USA.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.
Further information
Media:
Katrine Sperling
+45-4442-6718
krsp@novonordisk.com
Ken Inchausti (US)
+1-609-514-8316
kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen
+45-4442-4303
krop@novonordisk.com
Frank Daniel Mersebach
Daniel Bohsen
+45-4442-0604
+45-3079-6376
fdni@novonordisk.com
dabo@novonordisk.com
Lars Borup Jacobsen
+45-3075-3479
lbpj@novonordisk.com
Jannick Lindegaard (US)
+1-609-786-4575
jlis@novonordisk.com
_______________________
References
Video: http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control